Upadacitinib in patients from China, Brazil, and South Korea with rheumatoid arthritis and an inadequate response to conventional therapy-Reference-Cited by-同舟云学术

Upadacitinib in patients from China, Brazil, and South Korea with rheumatoid arthritis and an inadequate response to conventional therapy

Published:2021-11-15 Issue:12 Volume:24 Page:1530-1539
ISSN:1756-1841
Container-title:International Journal of Rheumatic Diseases
language:en
Short-container-title:Int J Rheum Dis

Author:

Zeng Xiaofeng¹²,Zhao Dongbao³,Radominski Sebastiao C.⁴,Keiserman Mauro⁵,Lee Chang K.⁶,Meerwein Sebastian⁷,Enejosa Jeffrey⁸,Sui Yunxia⁸,Mohamed Mohamed‐Eslam F.⁸,Park Won⁹

Affiliation:

1. Department of Rheumatology Peking Union Medical College Hospital (PUMCH) Chinese Academy of Medical Sciences Beijing China

2. Key Laboratory of Rheumatology & Clinical Immunology National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC‐DID) Beijing China

3. Department of Rheumatology and Immunology Shanghai Changhai Hospital Shanghai China

4. Department of Rheumatology Universidade Federal do Paraná Curitiba Brazil

5. Department of Rheumatology Pontifical Catholic University Porto Alegre Brazil

6. Rheumatology Asan Medical Center Seoul South Korea

7. Immunology AbbVie Deutschland GmbH & Co. KG Ludwigshafen Germany

8. Immunology AbbVie Inc. Chicago Illinois USA

9. Rheumatology School of Medicine Inha University Incheon South Korea

Funder

AbbVie

Publisher

Wiley

Subject